An altered peripheral IL6 response in major depressive disorder

Neurobiology of Disease

Volumn 89, Issue , 2016, Pages 46-54

  Money, Kelli M ^a   Olah, Zita ^b,d   Korade, Zeljka ^b,c   Garbett, Krassimira A ^b   Shelton, Richard C ^e   Mirnics, Karoly ^b,c  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF SZEGED   (Hungary)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Cytokine; Fibroblasts; IL1b; IL6; Inflammation; Lipid metabolism; Major depressive disorder; Mitochondrial function; Oxidative stress; TNFa

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA; SOCS3 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AMINO ACID METABOLISM; APOPTOSIS; ARTICLE; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DNA SYNTHESIS; FEMALE; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; HUMAN; HUMAN CELL; IL6 GENE; IMMUNE RESPONSE; LIPID METABOLISM; MAJOR DEPRESSION; MALE; MITOCHONDRION; MOLECULAR DYNAMICS; OXIDATIVE STRESS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ISOLATION; SIGNAL TRANSDUCTION; CELL CULTURE; DERMIS; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; INFLAMMATION; METABOLISM;

CELLS, CULTURED; DEPRESSIVE DISORDER, MAJOR; DERMIS; FEMALE; FIBROBLASTS; GENE EXPRESSION PROFILING; HUMANS; INFLAMMATION; INTERLEUKIN-1BETA; INTERLEUKIN-6; MITOCHONDRIA; OXIDATIVE STRESS; SUPPRESSOR OF CYTOKINE SIGNALING 3 PROTEIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84956642768     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2016.01.015     Document Type: Article

References (112)

1. Akin D., et al. Signal transduction abnormalities in melancholic depression. Int. J. Neuropsychopharmacol. 2005, 8:5-16.
2. Al-Damluji S. The mechanism of action of antidepressants: a unitary hypothesis based on transport-p. Curr. Drug Targets CNS Neurol. Disord. 2004, 3:201-216.
3. Alexopoulos G.S. Depression in the elderly. Lancet 2005, 365:1961-1970.
4. Allen A.M., Graham A. Mitochondrial function is involved in regulation of cholesterol efflux to apolipoprotein (apo)A-I from murine RAW 264.7 macrophages. Lipids Health Dis. 2012, 11:169.
5. Andres V., et al. Macrophage proliferation and apoptosis in atherosclerosis. Curr. Opin. Lipidol. 2012, 23:429-438.
6. Arion D., et al. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol. Psychiatry 2007, 62:711-721.
7. Association A.P. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR 2000, American Psychiatric Association, Washington, DC.
8. Babon J.J., et al. Suppression of cytokine signaling by SOCS3: characterization of the mode of inhibition and the basis of its specificity. Immunity 2012, 36:239-250.
9. Babon J.J., et al. Inhibition of IL-6 family cytokines by SOCS3. Semin. Immunol. 2014, 26:13-19.
10. Badger A.M., et al. SB 203580 inhibits p38 mitogen-activated protein kinase, nitric oxide production, and inducible nitric oxide synthase in bovine cartilage-derived chondrocytes. J. Immunol. 1998, 161:467-473.
11. Bahn S., Chan M.K. What can we learn about depression from gene expression in peripheral tissues?. Biol. Psychiatry 2015, 77:207-209.
12. Bakunina N., et al. Immune mechanisms linked to depression via oxidative stress and neuroprogression. Immunology 2015, 44:365-373.
13. Besedovsky H.O., et al. Cytokines as modulators of the hypothalamus-pituitary-adrenal axis. J. Steroid Biochem. Mol. Biol. 1991, 40:613-618.
14. Bresciani G., et al. Manganese superoxide dismutase and oxidative stress modulation. Adv. Clin. Chem. 2015, 68:87-130.
15. Bryan H.K., et al. The Nrf2 cell defence pathway: Keap1-dependent and -independent mechanisms of regulation. Biochem. Pharmacol. 2013, 85:705-717.
16. Capuron L., et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
17. Carpenter L.L., et al. Association between plasma IL-6 response to acute stress and early-life adversity in healthy adults. Neuropsychopharmacology 2010, 35:2617-2623.
18. Chourbaji S., et al. IL-6 knockout mice exhibit resistance to stress-induced development of depression-like behaviors. Neurobiol. Dis. 2006, 23:587-594.
19. Cyster J.G., et al. 25-Hydroxycholesterols in innate and adaptive immunity. Nat. Rev. Immunol. 2014, 14:731-743.
20. Czarny P., et al. Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder. Med. Sci. Monit. 2015, 21:412-418.
21. Dahl J., et al. The plasma levels of various cytokines are increased during ongoing depression and are reduced to normal levels after recovery. Psychoneuroendocrinology 2014, 45:77-86.
22. Degos B., et al. POLG mutations associated with remitting/relapsing neurological events. J. Clin. Neurosci. 2014, 21:186-188.
23. Dickens C., et al. Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom. Med. 2002, 64:52-60.
24. Dowlati Y., et al. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
25. Eaton W.W., et al. Population-based study of first onset and chronicity in major depressive disorder. Arch. Gen. Psychiatry 2008, 65:513-520.
26. Erdem M., et al. Serum haptoglobin levels in patients with melancholic and nonmelancholic major depression. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 2011, 35:944-947.
27. Fernandez-Estevez M.A., et al. Trehalose reverses cell malfunction in fibroblasts from normal and Huntington's disease patients caused by proteosome inhibition. PLoS One 2014, 9.
28. First M.B., et al. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition. (SCID-I/P) 2002, Biometrics Research, New York State Psychiatric Institute, New York, NY.
29. Fischer P., et al. The role of the inhibitors of interleukin-6 signal transduction SHP2 and SOCS3 for desensitization of interleukin-6 signalling. Biochem. J. 2004, 378:449-460.
30. Fujigaki H., et al. The signal transducer and activator of transcription 1alpha and interferon regulatory factor 1 are not essential for the induction of indoleamine 2,3-dioxygenase by lipopolysaccharide: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB pathways, and synergistic effect of several proinflammatory cytokines. J. Biochem. 2006, 139:655-662.
31. Garbett K.A., et al. Effects of maternal immune activation on gene expression patterns in the fetal brain. Transl. Psychiatry 2012, 2.
32. Garbett K.A., et al. Coordinated messenger RNA/microRNA changes in fibroblasts of patients with major depression. Biol. Psychiatry 2015, 77:256-265.
33. Garbett K.A., et al. Fibroblasts from patients with major depressive disorder show distinct transcriptional response to metabolic stressors. Transl. Psychiatry 2015, 5.
34. Gaspar L., et al. Human cellular differences in cAMP-CREB signaling correlate with light-dependent melatonin suppression and bipolar disorder. Eur. J. Neurosci. 2014, 40:2206-2215.
35. Ghisletti S., et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPARgamma. Mol. Cell 2007, 25:57-70.
36. Gibson S.A., et al. Oxidative stress and glutathione response in tissue cultures from persons with major depression. J. Psychiatr. Res. 2012, 46:1326-1332.
37. Graff L.A., et al. Depression and anxiety in inflammatory bowel disease: a review of comorbidity and management. Inflamm. Bowel Dis. 2009, 15:1105-1118.
38. Graham A., Allen A.M. Mitochondrial function and regulation of macrophage sterol metabolism and inflammatory responses. World J. Cardiol. 2015, 7:277-286.
39. Grivennikov S., Karin M. Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 2010, 21:11-19.
40. Guan Z., et al. Induction of cyclooxygenase-2 by the activated MEKK1 → SEK1/MKK4→ p38 mitogen-activated protein kinase pathway. J. Biol. Chem. 1998, 273:12901-12908.
41. Guo J.Y., et al. 2-Methoxycinnamaldehyde reduces IL-1beta-induced prostaglandin production in rat cerebral endothelial cells. Biol. Pharm. Bull. 2006, 29:2214-2221.
42. Hanisch A., et al. Timely anaphase onset requires a novel spindle and kinetochore complex comprising Ska1 and Ska2. EMBO J. 2006, 25:5504-5515.
43. Hayashi T., et al. MAM: more than just a housekeeper. Trends Cell Biol. 2009, 19:81-88.
44. Heinrich P.C., et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem. J. 2003, 374:1-20.
45. Himmerich H., et al. Regulatory T cells increased while IL-1beta decreased during antidepressant therapy. J. Psychiatr. Res. 2010, 44:1052-1057.
46. Hodes G.E., et al. Individual differences in the peripheral immune system promote resilience versus susceptibility to social stress. Proc. Natl. Acad. Sci. U. S. A. 2014, 111:16136-16141.
47. Hollenbach E., et al. Inhibition of p38 MAP kinase- and RICK/NF-κB-signaling suppresses inflammatory bowel disease. FASEB J. 2004.
48. Howren M.B., et al. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
49. Jia H., et al. HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation. Proc. Natl. Acad. Sci. U. S. A. 2015, 112:E56-E64.
50. Johansson A.S., et al. Activation of kynurenine pathway in ex vivo fibroblasts from patients with bipolar disorder or schizophrenia: cytokine challenge increases production of 3-hydroxykynurenine. J. Psychiatr. Res. 2013, 47:1815-1823.
51. Kalman S., et al. Metabolic stress-induced microRNA and mRNA expression profiles of human fibroblasts. Exp. Cell Res. 2014, 320:343-353.
52. Karry R., et al. Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study. Biol. Psychiatry 2004, 55:676-684.
53. Kershaw N.J., et al. SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat. Struct. Mol. Biol. 2013, 20:469-476.
54. Kessler R.C., et al. Lifetime prevalence and age-of-onset distributions of dsm-iv disorders in the national comorbidity survey replication. Arch. Gen. Psychiatry 2005, 62:593-602.
55. Krishnadas R., et al. P01-380 - correlates of depression and quality of life in patients with inflammatory arthritides. Eur. Psychiatry 2011, 26(Supplement 1):383.
56. Krishnan R., et al. Effects of etanercept therapy on fatigue and symptoms of depression in subjects treated for moderate to severe plaque psoriasis for up to 96 weeks. Br. J. Dermatol. 2007, 157:1275-1277.
57. Kumari D., et al. Identification of fragile X syndrome specific molecular markers in human fibroblasts: a useful model to test the efficacy of therapeutic drugs. Hum. Mutat. 2014, 35:1485-1494.
58. Lalovic A., et al. Altered expression of lipid metabolism and immune response genes in the frontal cortex of suicide completers. J. Affect. Disord. 2010, 120:24-31.
59. Las G., Shirihai O.S. Miro1: new wheels for transferring mitochondria. EMBO J. 2014, 33:939-941.
60. Lawlor K.E., Vince J.E. Ambiguities in NLRP3 inflammasome regulation: is there a role for mitochondria?. Biochim. Biophys. Acta 2014, 1840:1433-1440.
61. LeMay L.G., et al. The effects of psychological stress on plasma interleukin-6 activity in rats. Physiol. Behav. 1990, 47:957-961.
62. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
63. Li W., et al. Regulation of noradrenergic function by inflammatory cytokines and depolarization. J. Neurochem. 2003, 86:774-783.
64. Lisi L., et al. Monocytes from depressed patients display an altered pattern of response to endotoxin challenge. PLoS One 2013, 8.
65. Liu Y., et al. Mesenchymal stem cell-based tissue regeneration is governed by recipient T lymphocytes via IFN-[gamma] and TNF-[alpha]. Nat. Med. 2011, 17:1594-1601.
66. Liu F., et al. IKK biology. Immunol. Rev. 2012, 246:239-253.
67. Lo Fermo S., et al. Outcome of psychiatric symptoms presenting at onset of multiple sclerosis: a retrospective study. Mult. Scler. 2010, 16:742-748.
68. Lukic I., et al. Lymphocyte levels of redox-sensitive transcription factors and antioxidative enzymes as indicators of pro-oxidative state in depressive patients. Neuropsychobiology 2014, 70:1-9.
69. Maes M., et al. Relationships between lower plasma l-tryptophan levels and immune-inflammatory variables in depression. Psychiatry Res. 1993, 49:151-165.
70. Maes M., et al. Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression. Psychiatry Res. 1993, 49:11-27.
71. Maes M., et al. Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine 1997, 9:853-858.
72. Manier D.H., et al. Human fibroblasts as a relevant model to study signal transduction in affective disorders. J. Affect. Disord. 2000, 61:51-58.
73. Manji H., et al. Impaired mitochondrial function in psychiatric disorders. Nat. Rev. Neurosci. 2012, 13:293-307.
74. McCarthy M.J., et al. Genetic and clinical factors predict lithium's effects on PER2 gene expression rhythms in cells from bipolar disorder patients. Transl. Psychiatry 2013, 3.
75. Moieni M., et al. Sex differences in depressive and socioemotional responses to an inflammatory challenge: implications for sex differences in depression. Neuropsychopharmacology 2015, 40:1709-1716.
76. Monje F.J., et al. Constant darkness induces IL-6-dependent depression-like behavior through the NF-kappaB signaling pathway. J. Neurosci. 2011, 31:9075-9083.
77. Moussavi S., et al. Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
78. Müller C.P., et al. Brain membrane lipids in major depression and anxiety disorders. Biochim. Biophys. Acta Mol. Cell Biol. Lipids 2015, 1851:1052-1065.
79. Musselman D.L., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
80. Ness G.C. Physiological feedback regulation of cholesterol biosynthesis: role of translational control of hepatic HMG-CoA reductase and possible involvement of oxylanosterols. Biochim. Biophys. Acta 2015, 1851:667-673.
81. Niemand C., et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. J. Immunol. 2003, 170:3263-3272.
82. Noto C., et al. Targeting the inflammatory pathway as a therapeutic tool for major depression. Neuroimmunomodulation 2014, 21:131-139.
83. Pace T.W., et al. Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am. J. Psychiatry 2006, 163:1630-1633.
84. Perregaux D.G., et al. Inhibition of interleukin-1 beta production by SKF86002: evidence of two sites of in vitro activity and of a time and system dependence. Mol. Pharmacol. 1995, 48:433-442.
85. Powell T.R., et al. Putative transcriptomic biomarkers in the inflammatory cytokine pathway differentiate major depressive disorder patients from control subjects and bipolar disorder patients. PLoS One 2014, 9.
86. Quak J., et al. Does tryptophan degradation along the kynurenine pathway mediate the association between pro-inflammatory immune activity and depressive symptoms?. Psychoneuroendocrinology 2014, 45:202-210.
87. Raison C.L., et al. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol. 2006, 27:24-31.
88. Raison C.L., et al. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
89. Reichenberg A., et al. Interferon-induced depression and cognitive impairment in hepatitis C virus patients: a 72 week prospective study. AIDS 2005, 19(Suppl. 3):S174-S178.
90. Reus G.Z., et al. Ketamine ameliorates depressive-like behaviors and immune alterations in adult rats following maternal deprivation. Neurosci. Lett. 2015, 584:83-87.
91. Roose S.P., Schatzberg A.F. The efficacy of antidepressants in the treatment of late-life depression. J. Clin. Psychopharmacol. 2005, 25:S1-S7.
92. Setiawan E., et al. Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. JAMA Psychiatry 2015, 72:268-275.
93. Sharpe L.J., Brown A.J. Controlling cholesterol synthesis beyond 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR). J. Biol. Chem. 2013, 288:18707-18715.
94. Shelton R.C., et al. cAMP-dependent protein kinase activity in major depression. Am. J. Psychiatry 1996, 153:1037-1042.
95. Shelton R.C., et al. Differential expression of pentraxin 3 in fibroblasts from patients with major depression. Neuropsychopharmacology 2004, 29:126-132.
96. Shelton R.C., et al. Altered expression of genes involved in inflammation and apoptosis in frontal cortex in major depression. Mol. Psychiatry 2011, 16:751-762.
97. Shibata N., Glass C.K. Macrophages, oxysterols and atherosclerosis. Circ. J. 2010, 74:2045-2051.
98. Shimizu S., et al. An allel-specific abnormal transcript of the heat shock protein 70 gene in patients with major depression. Biochem. Biophys. Res. Commun. 1996, 219:745-752.
99. Slavich G.M., Irwin M.R. From stress to inflammation and major depressive disorder: a social signal transduction theory of depression. Psychol. Bull. 2014, 140:774-815.
100. Spinazzola A., Zeviani M. Disorders from perturbations of nuclear-mitochondrial intergenomic cross-talk. J. Intern. Med. 2009, 265:174-192.
101. Su S., et al. Common genetic contributions to depressive symptoms and inflammatory markers in middle-aged men: the Twins Heart Study. Psychosom. Med. 2009, 71:152-158.
102. Sukoff Rizzo S.J., et al. Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl. Psychiatry 2012, 2.
103. Tak P.P., Firestein G.S. NF-κB: a key role in inflammatory diseases. J. Clin. Invest. 2001, 107:7-11.
104. Tobe E.H. Mitochondrial dysfunction, oxidative stress, and major depressive disorder. Neuropsychiatr. Dis. Treat. 2013, 9:567-573.
105. Traversari C., Russo V. Control of the immune system by oxysterols and cancer development. Curr. Opin. Pharmacol. 2012, 12:729-735.
106. Tyring S., et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
107. Voorhees J.L., et al. Prolonged restraint stress increases IL-6, reduces IL-10, and causes persistent depressive-like behavior that is reversed by recombinant IL-10. PLoS One 2013, 8.
108. Yiend J., et al. Long term outcome of primary care depression. J. Affect. Disord. 2009, 118:79-86.
109. Yirmiya R., et al. Illness, cytokines, and depression. Ann. N. Y. Acad. Sci. 2000, 917:478-487.
110. Zarubin T., Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res. 2005, 15:11-18.
111. Zorumski C.F., et al. Neurosteroids, stress and depression: potential therapeutic opportunities. Neurosci. Biobehav. Rev. 2013, 37:109-122.
112. van Zuiden M., et al. IL-1beta reactivity and the development of severe fatigue after military deployment: a longitudinal study. J. Neuroinflammation 2012, 9:205.